Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
August 03 2017 - 8:01AM
Zug, Switzerland, August 3, 2017 - Auris Medical
Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in otolaryngology, today announced that it will report its
financial results for the second quarter of 2017 on Thursday,
August 10, 2017. Following the announcement, Auris Medical's
management team will host a live conference call and webcast at
8:00 am Eastern Time (2:00 pm Central European Time) to discuss the
Company's financial results and to provide a general business
update.
To participate in this conference call, dial
1-877-280-1254 (USA) or +1-212-444-0896 (International), and enter
passcode 1366409. A live webcast of the conference call can be
accessed on the Investor Relations section of the Auris Medical
website at www.aurismedical.com. A replay will be available
approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology. The company is focused on the Phase 3
development of treatments for acute inner ear hearing loss (AM-111)
and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of
intratympanic administration with biocompatible gel formulations.
In addition, Auris Medical is developing intranasal betahistine for
Meniere's disease and other vestibular disorders (AM-125) as well
as early-stage research and development projects. The Company was
founded in 2003 and is headquartered in Zug, Switzerland. The
shares of Auris Medical Holding AG trade on the NASDAQ Global
Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024